PRAX: FDA Grants Breakthrough Therapy
Praxis Precision Medicines receives Breakthrough Therapy designation from FDA for Elsunersen to treat seizures associated with SCN2A development and epileptic encephalopathy
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.